JAK抑制剂与恶性肿瘤风险:跨疾病适应症的荟萃分析
该系统评价与网络荟萃分析纳入62项随机对照试验和16项长期扩展研究,比较JAK抑制剂与安慰剂、TNF-α抑制剂或甲氨蝶呤的恶性肿瘤发生率。JAK抑制剂总体恶性肿瘤发生率在随机对照试验中为每100人年1.15,合并数据为每100人年1.26。与TNF-α抑制剂相比,JAK抑制剂与恶性肿瘤发生率升高相关(IRR 1.50;95%CI 1.16至1.94),与安慰剂或甲氨蝶呤相比无显著差异。
要点
- JAK抑制剂与TNF-α抑制剂相比恶性肿瘤发生率升高(IRR 1.50;95%CI 1.16至1.94)。
- JAK抑制剂与安慰剂(IRR 0.71;95%CI 0.44至1.15)或甲氨蝶呤(IRR 0.77;95%CI 0.35至1.68)相比无显著差异。
- 所有比较中恶性肿瘤均为罕见事件;仅分析非黑色素瘤皮肤癌或合并随机对照试验/长期扩展数据时结果一致。
核心结论
- JAK抑制剂与TNF-α抑制剂相比恶性肿瘤发生率更高,但与安慰剂或甲氨蝶呤相比无显著差异。
- 所有比较中恶性肿瘤均为罕见事件。
研究设计与样本
- 系统检索数据库至2022年12月,纳入JAK抑制剂(托法替布、巴瑞替尼、乌帕替尼、非戈替尼、培非替尼)对比安慰剂、TNF-α抑制剂或甲氨蝶呤的II/III/IV期随机对照试验和长期扩展研究。
- 研究对象为患有类风湿关节炎、银屑病关节炎、银屑病、中轴型脊柱关节炎、炎症性肠病或特应性皮炎的成人。
- 共纳入62项随机对照试验和16项长期扩展研究,JAK抑制剂暴露82366人年,安慰剂2924人年,TNF-α抑制剂7909人年,甲氨蝶呤1074人年。
- 采用网络荟萃分析和配对荟萃分析估计恶性肿瘤发生率比值(IRR),使用Cochrane偏倚风险-2工具评估偏倚。
主要发现
- 随机对照试验中总体恶性肿瘤发生率为每100人年1.15,合并随机对照试验和长期扩展数据为每100人年1.26。
- 网络荟萃分析中,JAK抑制剂与安慰剂相比全部恶性肿瘤(包括非黑色素瘤皮肤癌)发生率无显著差异(IRR 0.71;95%CI 0.44至1.15)。
- JAK抑制剂与甲氨蝶呤相比全部恶性肿瘤发生率无显著差异(IRR 0.77;95%CI 0.35至1.68)。
- JAK抑制剂与TNF-α抑制剂相比恶性肿瘤发生率升高(IRR 1.50;95%CI 1.16至1.94)。
- 仅分析非黑色素瘤皮肤癌时以及合并随机对照试验/长期扩展数据时,结果一致。
关键数值与推荐
- JAK抑制剂 vs 安慰剂:全部恶性肿瘤(包括非黑色素瘤皮肤癌)IRR 0.71(95%CI 0.44至1.15)。
- JAK抑制剂 vs 甲氨蝶呤:全部恶性肿瘤IRR 0.77(95%CI 0.35至1.68)。
- JAK抑制剂 vs TNF-α抑制剂:恶性肿瘤IRR 1.50(95%CI 1.16至1.94)。
- 随机对照试验中恶性肿瘤总发生率为每100人年1.15;合并随机对照试验和长期扩展数据为每100人年1.26。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate. METHODS: Systematic searches of databases were performed, to December 2022, to identify phase II/III/IV randomised clinical trials (RCTs) and long-term extension (LTE) studies of JAKi (tofacitinib, baricitinib, upadacitinib, filgotinib, peficitinib) compared with placebo, TNFi or methotrexate, in adults with rheumatoid arthritis, psoriatic arthritis, psoriasis, axial spondyloarthritis, inflammatory bowel disease or atopic dermatitis. Network and pairwise meta-analyses were performed to estimate incidence rate ratios (IRRs) for malignancy between JAKi and comparators. Bias was assessed using the Cochrane Risk of Bias-2 tool. RESULTS: In 62 eligible RCTs and 16 LTE studies, there were 82 366 person-years of exposure to JAKi, 2924 to placebo, 7909 to TNFi and 1074 to methotrexate. The overall malignancy incidence rate was 1.15 per 100 person-years in RCTs, and 1.26 per 100 person-years across combined RCT and LTE data. In network meta-analyses, the incidence of all malignancies including non-melanomatous skin cancers (NMSCs) was not significantly different between JAKi and placebo (IRR 0.71; 95% CI 0.44 to 1.15) or between JAKi and methotrexate (IRR 0.77; 95% CI 0.35 to 1.68). Compared with TNFi, however, JAKi were associated with an increased incidence of malignancy (IRR 1.50; 95% CI 1.16 to 1.94). Findings were consistent when analysing NMSC only and when analysing combined RCT/LTE data. CONCLUSIONS: JAKi were associated with a higher incidence of malignancy compared with TNFi but not placebo or methotrexate. Cancers were rare events in all comparisons. PROSPERO REGISTRATION NUMBER: CRD42022362630.
引用
- Russell MD, Stovin C, Alveyn E, et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023. PMID: 37247942. doi:10.1136/ard-2023-224049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。